CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 3555993
• 负责人: MARK R. GREEN
• 金额: $ 12.78万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-04-01 至 1988-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3555993
• 关键词: 6 thioguanine; 6 thiopurine; Hodgkin's disease; asparaginase; bleomycin; cancer information system; carmustine; cellular oncology; combination cancer therapy; cooperative study; cytosine arabinoside; dacarbazine; daunorubicin; doxorubicin; drug metabolism; enzyme therapy; histiocytic lymphoma; human subject; human therapy evaluation; lomustine; lymphocytic leukemia; lymphoma; lymphosarcoma; membrane activity; methotrexate; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; nephroblastoma; neuroblastoma; pediatric neoplasm /cancer; pediatric pharmacology; prednisone; procarbazine; rhabdomyosarcoma; vinblastine; vincristine

The listed investigators at the University of California San Diego School of Medicine and adjunct institutions plan to continue active, multidisciplinary membership in Cancer and Leukemia Group B (CALGB). We aim to (1) increase accrual to Group studies (to a projected total of 110-125 patients/year), (2) participate in directing intellectual productivity of the Group (by stimulating more basic research components to clinical trials, designing and chairing protocol, presenting pilot observation for Group validation and expansion), 3) increase involvement in Group administrative activities (by accepting appointments as committee chairs, core committee members, protocol chairs) (4) provide direct service to the Group (by maintaining an active Cell Surface Marker Reference Laboratory of exceptionally high technical quality and scientific sophistication and serving as the Institutional base for expanding microcomputer applications for CALGB as a whole), and (5) serve as a clinical resource and multidisciplinary research base for CCOP activities (which will further enhance accrual to CALGB trails). Continued participation in CALGB will measurably improve the overall quality of Oncology care delivered in the entire San Diego area and serve as an important educational vehicle for Faculty, Fellows, Housestaff and students at UCSD and affiliated participants. Increased staff and trainee participation in CALGB activities offer an expanded patient base (at San Diego VA Medical Center, Naval Regional Medical Center, in the private San Diego Oncology Community, and at our CCOP affiliate in Las Vegas, Nevada) and entry of all eligible patients on appropriate CALGB trials (facilitated by increased data management/secretarial services) should permit achievement of accrual goals. Increased participation at CALGB national meetings by physicians and staff from UCSD should lead to new committee appointments, protocol development opportunities, and broadened intellectual input from our institution. The basic science resources of the UCSD Cancer Center will be available to provide laboratory research components for new trials. The Cell Surface Marker Reference Laboratory can expand its contributions as further Group protocols are developed which utilize its sophisticated capabilities. This overall participation will hopefully allow both UCSD and CALGB to make meaningful contributions toward the cure of cancer.

加利福尼亚大学圣地亚哥大学的列出的调查员 医学和辅助机构计划继续活跃， 癌症和白血病B（CALGB）的多学科会员资格。 我们 目的是（1）增加对小组研究的应计（预计总计 110-125名患者/年），（2）参与指导智力 小组的生产力（通过刺激更多的基础研究组件 临床试验，设计和主席协议，提出飞行员 观察小组验证和扩展），3）增加参与 小组行政活动（通过接受任命为委员会 椅子，核心委员会成员，协议主席）（4）提供直接服务 到该组（通过维持活性细胞表面标记参考 极高的技术质量和科学的实验室 精致，作为扩展的机构基础 整个CALGB的微型计算机应用），（5）用作 CCOP活动的临床资源和多学科研究基础 （这将进一步增强Calgb步道的应计）。 持续 参与CALB将可以衡量地提高总体质量 在整个圣地亚哥地区提供的肿瘤学护理，并作为 教师，研究员，Housestaff和学生的重要教育工具 在UCSD和附属参与者。 增加员工和受训者参加Calgb活动提供了 扩大的患者基础（在海军地区圣地亚哥弗吉尼亚州医疗中心 医疗中心，圣地亚哥私人肿瘤学社区以及我们的 内华达州拉斯维加斯的CCOP分支机构，所有合格患者的进入 适当的小腿试验（通过增加数据促进 管理/秘书服务）应允许获得应计 目标。 医生增加了CALGB国家会议的参与 UCSD的工作人员应导致新的委员会任命，协议 开发机会，并从我们的 机构。 UCSD癌症中心的基础科学资源将是 可用于提供新试验的实验室研究组件。 这 细胞表面标记参考实验室可以扩大其贡献 开发了进一步的小组协议，该协议利用其复杂的 功能。 这一总体参与将有望允许两家UCSD 和小牛为治愈癌症做出有意义的贡献。